Remove 2024 Remove Diabetes Remove Immunity
article thumbnail

Top 20 global biopharma companies report 4.3% growth in market capitalisation in Q2 2024, reveals GlobalData

Express Pharma

The biopharmaceutical industry remained resilient in the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve. trillion as on 31 March 2024 to $4 trillion as on 30 June 2024, reveals GlobalData.

article thumbnail

US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk

Express Pharma

Adults with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes (3) are at increased risk for severe consequences from an RSV infection compared to those without these conditions. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation or death.(4)

Vaccines 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines

Express Pharma

Ophelia Chan, Business Fundamentals Senior Analyst at GlobalData, comments, “The COVID-19 pandemic highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing- factors that drove the success of mRNA-based COVID-19 vaccines.” billion in July 2024.

Vaccines 104
article thumbnail

New Year, New Goals: 2024

The Thyroid Pharmacist

I am hoping to feel more settled in 2024. I am wrapping up some projects in early 2024 and I am carving out more time for myself and my own healing. Adaptogens may also be anti-inflammatory, neuroprotective, and supportive of a healthy immune function. Does Adrenal Fatigue Exist? Gut Recovery Program (est.

article thumbnail

Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directors

Putting Patients First Blog

Jeff Todd , President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. Jeff Todd , President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024.

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.